Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 May;99(5):378-384.
doi: 10.1308/rcsann.2017.0024.

Postoperative survival following perioperative MAGIC versus neoadjuvant OE02-type chemotherapy in oesophageal adenocarcinoma

A M Reece-Smith  1 , J H Saunders  1 , I N Soomro  1 , C R Bowman  1 , J P Duffy  1 , P V Kaye  1 , N T Welch  1 , S Madhusudan  1 , S L Parsons  1
Affiliations

Postoperative survival following perioperative MAGIC versus neoadjuvant OE02-type chemotherapy in oesophageal adenocarcinoma

A M Reece-Smith et al. Ann R Coll Surg Engl. 2017 May.

Abstract

The optimal management of resectable oesophageal adenocarcinoma is controversial, with many centres using neoadjuvant chemotherapy following the Medical Research Council (MRC) oesophageal working group (OE02) trial and the MRC Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial. The more intensive MAGIC regimen is used primarily in gastric cancer but some also use it for oesophageal cancer. A database of cancer resections (2001-2013) provided information on survival of patients following either OE02 or MAGIC-type treatment. The data were compared using Kaplan-Meier analysis. Straight-to-surgery patients were also reviewed and divided into an 'early' cohort (2001-2006, OE02 era) and a 'late' cohort (2006-2013, MAGIC era) to estimate changes in survival over time. Subgroup analysis was performed for responders (tumour regression grade [TRG] 1-3) versus non-responders (TRG 4 and 5) and for anatomical site (gastro-oesophageal junction [GOJ] vs oesophagus). An OE02 regimen was used for 97 patients and 275 received a MAGIC regimen. Those in the MAGIC group were of a similar age to those undergoing OE02 chemotherapy but the proportion of oesophageal cancers was higher among MAGIC patients than among those receiving OE02 treatment. MAGIC patients had a significantly lower stage following chemotherapy than OE02 patients and a higher median overall survival although TRG was similar. On subgroup analysis, this survival benefit was maintained for GOJ and oesophageal cancer patients as well as non-responders. Analysis of responders showed no difference between regimens. 'Late' group straight-to-surgery patients were significantly older than those in the 'early' group. Survival, however, was not significantly different for these two cohorts. Although the original MAGIC trial comprised few oesophageal cancer cases, our patients had better survival with MAGIC than with OE02 chemotherapy in all anatomical subgroups, even though there was no significant change in operative survival over the time period in which these patients were treated. The use of the MAGIC regimen should therefore be encouraged in cases of operable oesophagogastric adenocarcinoma.

Keywords: Adenocarcinoma; Kaplan–Meier estimate; Neoadjuvant chemotherapy; Oesophageal neoplasm.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan–Meier survival analysis of all patients with oesophageal and gastro-oesophageal junction adenocarcinomas who received either OE02 or MAGIC-type chemotherapy prior to surgery
Figure 2
Figure 2
Kaplan–Meier subgroup analysis of patients with oesophageal cancer (A) and gastro-oesophageal junction cancer (B) who received either OE02 or MAGIC-type chemotherapy prior to surgery
Figure 3
Figure 3
Kaplan–Meier survival analysis of patients undergoing resection who had a good response (A) or a poor response (B) following either OE02 or MAGIC-type chemotherapy
See this image and copyright information in PMC

References

    1. van Hagen P, Hulshof MC, van Lanschot JJ et al. . Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012; : 2,074–2,084. - PubMed
    1. Cunningham D, Allum WH, Stenning SP et al. . Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; : 11–20. - PubMed
    1. Hyngstrom JR, Posner MC. Neoadjuvant strategies for the treatment of locally advanced esophageal cancer. J Surg Oncol 2010; : 299–304. - PubMed
    1. Medical Research Council Oesophageal Cancer Working Party. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002; : 1,727–1,733. - PubMed
    1. National Oesophago-Gastric Cancer Audit 2010. Leeds: NHS Information Centre; 2010.

Substances

Supplementary concepts